FY2025 · ended Dec 31, 2025 · Revenue $48.47M, -57.7% YoY · Filed Mar 17, 2026
Gossamer Bio, Inc. (GOSS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $48.5 million and a net loss of $170.4 million. Free cash flow was -$171.3 million. As of Jun 30, 2026 it held $57.0 million in cash and investments and $3.9 million in total debt.
Revenue (TTM)
$53.29M
+32.4% vs year-ago TTM
Net income (TTM)
$-125.22M
+9.7% vs year-ago TTM
Operating cash flow (TTM)
$-162.63M
-5.4% vs year-ago TTM
Free cash flow (TTM)
$-162.63M
EPS (TTM)
$-0.48
+20.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
234.70M
+3.3% vs prior year
Net cash
$53.10M
as of Jun 30, 2026
Operating margin
-311.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GOSS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1728117
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | — | — | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M |
| Diluted EPS | -$0.75 | -$0.25 | -$1.18 | -$2.71 | -$3.13 |
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M |
| Stockholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M |
| Cash and investments | $136.9M | $294.5M | $296.4M | $255.7M | $325.2M |
| Total debt | $4.4M | $5.4M | $15.9M | $30.0M | $35.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 28, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
All 484 Gossamer Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.